Investing.com - Avadel Pharma reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations.
Avadel Pharma announced earnings per share of $-0.330 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.300 on revenue of $0.
Avadel Pharma shares are down 28.9% from the beginning of the year, still down 50.43% from its 52 week high of $11.59 set on November 15, 2021.
Avadel Pharma shares lost 7.64% in intra-day trade following the report.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar